Researchers from TYK Medicines Inc. have reported the discovery and preclinical evaluation of TY-1091, a second-generation RET inhibitor being developed for the treatment of RET-mutant cancers.
Data on the poly(ADP-ribose) glycohydrolase (PARG) inhibitor SYX-3759, being investigated for the treatment of homologous recombination deficient (HRD) malignancies, were recently discussed by researchers from Hangzhou Synrx Therapeutics Technology Co. Ltd.
Researchers from Bliss Biopharmaceutical Co. Ltd. presented the discovery and preclinical evaluation of BB-1701, a new HER2-targeting eribulin-containing antibody-drug conjugate (ADC) being developed as a potential new anticancer agent.
Human natural killer (NK) cells play an essential role in tumor surveillance and can attack malignant cells in an antigen-independent manner. Because of this, allogeneic NK cells can be engineered as off-the-shelf therapies and may be used to target different hematological malignancies or solid tumors.
The B-raf kinase (BRAF oncogene) controls cell proliferation and survival through the mitogen-activated protein kinase (MAPK) pathway. By contrast, constitutively activated mutated BRAF causes uncontrolled tumorigenesis while small-molecule inhibition arrests growth to cause tumor regression.
T-cell exhaustion is a differentiation state of T cells associated with tumor progression in the context of cancer. One of the co-stimulatory molecules in the tumor microenvironment, 4-1BB, triggers a signaling cascade resulting in cytokine secretion and upregulation of antiapoptotic molecules.
Researchers from Hangzhou Polymed Biopharmaceuticals Inc. have reported the discovery and preclinical evaluation of HPB-092, an FMS-like tyrosine kinase 3 (FLT3) and interleukin-1 receptor-associated kinase 4 (IRAK-4) dual inhibitor, being developed for the treatment of acute myeloid leukemia (AML).
Tumor-infiltrating myeloid cells such as tumor-associated macrophages (TAMs) can suppress T-cell recruitment and function and promote the expansion and dissemination of cancer cells depending on their functional states. In hepatocellular carcinoma (HCC), TAMs are associated with resistance to sorafenib, the first-line treatment for advanced HCC.
Cytokines are potent immunomodulators with the potential to amplify cell-based immunity against cancer development. Interleukin-21 (IL-21) generates antitumor immunity by inducing B-cell activation and driving the development of antitumor T-cell response. The use of IL-21 in cancer treatment so far is limited due to inadequate pharmacokinetic properties and toxicity issues.
